STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 14, 2026, 07:06 AM

Hyperion DeFi Q1 Net Income $8.8M; Raises FY26 Guidance

AI Summary

Hyperion DeFi, Inc. announced record financial results for the first quarter ended March 31, 2026, with net income of $8.8 million and adjusted EBITDA of $19.5 million. The company also raised its full-year 2026 Adjusted Gross Profit guidance by approximately 20% to $5M-$7M, reflecting continued scaling of its DeFi operating businesses and accretive balance sheet growth. Additionally, Hyperion DeFi issued 132,249 shares of common stock, generating approximately $0.4 million in net proceeds.

Key Highlights

  • Hyperion DeFi reported record Q1 2026 Net Income of $8.8 million.
  • Adjusted EBITDA for Q1 2026 reached $19.5 million.
  • Adjusted Gross Profit increased 17% quarter-over-quarter to $960 thousand.
  • Company raised its FY 2026 Adjusted Gross Profit guidance to $5M-$7M, ~5x 2025 results.
  • Gross HYPE Tokens in treasury grew to over 2.00 million as of May 11, 2026.
  • Cash, cash equivalents, and USDH totaled $9.1 million in Q1 2026, increasing to $16.0 million by May 11, 2026.
  • Operating Expenses Excluding Stock-Based Compensation declined 1% quarter-over-quarter to $2.98 million.
  • Issued 132,249 shares of common stock for approximately $0.4 million in net proceeds.
HYPD
Biotechnology: Pharmaceutical Preparations
HYPERION DEFI, INC.

Price Impact